To interfere with PD-1 signaling to enhance immunotherapy for solid tumors, NK92 cells inspired a chimeric costimulatory converting receptor (CCCR) (CCCR-NK92) was established by Lu et al., and these CCCR-NK92 cells can reversed the immune suppressive effects of PD-1 by switching the negative PD-1 signal to an activating signal, and hence effectively enhanced the antitumor activity against H1299 cancer cells by triggering GSDME-induced pyroptosis (107). Here, GSDME is linked to cancer.